Home » Stocks » Intec Pharma

Intec Pharma Ltd. (NTEC)

Stock Price: $0.408 USD 0.020 (5.05%)
Updated Aug 7, 2020 3:39 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 28.27M
Revenue (ttm) n/a
Net Income (ttm) -33.75M
Shares Out 69.27M
EPS (ttm) -1.10
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 7, 2020
Last Price $0.408
Previous Close $0.389
Change ($) 0.020
Change (%) 5.05%
Day's Open 0.390
Day's Range 0.385 - 0.440
Day's Volume 9,350,612
52-Week Range 0.132 - 1.560

More Stats

Market Cap 28.27M
Enterprise Value 15.00M
Earnings Date (est) Nov 11, 2020
Ex-Dividend Date n/a
Shares Outstanding 69.27M
Float 56.40M
EPS (basic) -0.92
EPS (diluted) -1.10
FCF / Share -0.30
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 2.31M
Short Ratio 0.48
Short % of Float 2.57%
Beta 0.74
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 2.01
Revenue n/a
Operating Income -33.02M
Net Income -33.75M
Free Cash Flow -18.91M
Net Cash 13.26M
Net Cash / Share 0.19
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -42.80%
ROE -139.99%
ROIC -687.90%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (2)

Buy 0
Overweight 0
Hold 2
Underweight 0
Sell 0

Analyst Consensus: Hold

Price Target

$0.20*
Low
0.20
Current: $0.408
High
0.20
Target: 0.20
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year201920182017201620152014
Revenue------
Operating Income-47.11-43.33-29.44-13.81-7.58-5.78
Net Income-47.60-43.54-28.91-13.36-7.18-6.50
Shares Outstanding33.7831.1917.6611.45--
Earnings Per Share-1.41-1.40-1.64-1.17-0.92-1.18
Operating Cash Flow-29.05-39.08-22.13-12.01-7.93-4.75
Capital Expenditures-0.92-4.67-4.99-0.48-1.38-0.08
Free Cash Flow-29.97-43.74-27.13-12.49-9.32-4.83
Cash & Equivalents10.0640.5855.2218.2930.747.82
Total Debt0.80-----
Net Cash / Debt9.2640.5855.2218.2930.747.82
Assets21.2861.5164.5524.7237.1712.50
Liabilities9.757.975.752.021.643.02
Book Value11.5453.5558.8022.7035.539.48
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Intec Pharma Ltd.
Country Israel
Employees 38
CEO Jeffrey A. Meckler

Stock Information

Ticker Symbol NTEC
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: NTEC

Description

Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism. The company's lead product candidate is Accordion Pill Carbidopa/Levodopa, which is in a Phase III clinical trial for the treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients. It is also developing Accordion Pill Zaleplon that is in a Phase III clinical trial as a treatment for the induction and maintenance of sleep in patients suffering from insomnia; a product candidate, which has completed a Phase I clinical trial for the prevention and treatment of gastroduodenal and small bowel Nonsteroidal Anti-Inflammatory Drug induced ulcers; and AP-CBD/THC, AP-THC, and AP-CBD product candidates with Cannabidiol and 9-Tetrahydrocannabinol for the treatment of various indications, including low back pain, neuropathic pain, and fibromyalgia. Intec Pharma Ltd. has a research collaboration agreement with Merck to explore using the Accordion Pill platform for development program. The company was formerly known as Intec Pharmaceuticals (2000) Ltd. and changed its name to Intec Pharma Ltd. in March 2004. Intec Pharma Ltd. was founded in 2000 and is based in Jerusalem, Israel.